Neoplasms by Site × Cisplatin × Clear all
NCT04124198 2025-12-31

QoLATI

Rigshospitalet, Denmark

Phase NA Active not recruiting
138 enrolled
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled